4-[[4-[2-(2-Amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]butanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-[[4-[2-(2-Amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]butanoic acid
• 英文别名: 4-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]butanoic acid
• 化学式: C₁₉H₂₁N₅O₄
• 分子量: 383.4
• InChiKey: OYGLAQGVGCPYCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  150
• 氢给体数：
  5
• 氢受体数：
  4

文献信息

• [EN] TARGETED THERAPEUTICS<br/>[FR] THÉRAPEUTIQUE CIBLÉE
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2015038649A1

  公开（公告）日：2015-03-19

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

  本发明提供了包括与将效应子导向至感兴趣的生物靶点的结合基团共轭的药理化合物。同样，本发明提供了包括这些化合物的组合物、试剂盒和方法（例如治疗、诊断和成像）。这些化合物可以被描述为蛋白质相互作用结合基团-药物共轭（SDC-TRAP）化合物，其中包括蛋白质相互作用结合基团和效应子。例如，在针对治疗癌症的某些实施方式中，SDC-TRAP可以包括Hsp90抑制剂共轭到细胞毒性药剂作为效应子。
• COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES
  申请人：Cerulean Pharma Inc.

  公开号：EP3566719A1

  公开（公告）日：2019-11-13

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  本文提供了有关使用 CDP-治疗剂共轭物治疗自身免疫性疾病、炎症性疾病或癌症的方法。还提供了 CDP-治疗剂共轭物、包含 CDP-治疗剂共轭物的颗粒和包含 CDP-治疗剂共轭物的组合物。
• TARGETED THERAPEUTICS HAVING AN HSP90 LIGAND AS BINDING MOIETY
  申请人：Madrigal Pharmaceuticals, Inc.

  公开号：EP3738594A1

  公开（公告）日：2020-11-18

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions and therapeutic methods including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety which is an Hsp90 ligand and an effector moiety. The therapeutic uses include the treatment of cancer, chronic bronchitis, asthma, and actinic keratosis.

  本发明提供的药理化合物包括与结合基团共轭的效应分子，该结合基团可将效应分子导向感兴趣的生物靶标。同样，本发明还提供了包括这些化合物的组合物和治疗方法。这些化合物可以被描述为蛋白质相互作用结合分子-药物共轭物（SDC-TRAP）化合物，其中包括一个蛋白质相互作用结合分子（Hsp90 配体）和一个效应分子。治疗用途包括治疗癌症、慢性支气管炎、哮喘和日光性角化病。
• Pyrimidine compounds and pyrimido indole compounds and methods of use
  申请人：Duquesne University of the Holy Spirit

  公开号：US10774090B2

  公开（公告）日：2020-09-15

  The present invention discloses a compound comprising the formula: wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, or a compound of the formula wherein the S is replaced by CH2 or O, and optionally comprising a pharmaceutically acceptable salt or hydrate thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt or hydrate thereof.

  本发明公开了一种由式构成的化合物： 其中R为氢或具有一至十个碳原子的烷基，或式中S被CH2或O取代的化合物，并任选包括其药学上可接受的盐或水合物。一种治疗癌症或疾病患者的方法，包括向患者施用有效量的本发明化合物或其药学上可接受的盐或水合物。
• Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same
  申请人：Duquesne University of the Holy Spirit

  公开号：US11078214B2

  公开（公告）日：2021-08-03

  The present invention provides a compound of Formula XXVII: wherein X is CH2 or O, and R1 is H or CH3; or a salt or a hydrate of the compound, and further provides a pharmaceutical composition comprising the compound of Formula XXVII and one or more acceptable pharmaceutical carriers. A method of treating a patient having cancer comprising administering a therapeutically effective amount of a compound of Formula XXVII, or a pharmaceutical composition comprising a compound of Formula XXVII and one or more acceptable pharmaceutical carriers to the patient is disclosed.

  本发明提供了一种式 XXVII 的化合物： 其中X为CH2或O，R1为H或CH3；或该化合物的盐或水合物，并进一步提供了一种药物组合物，该组合物包含式XXVII化合物和一种或多种可接受的药物载体。本发明公开了一种治疗癌症患者的方法，包括向患者施用治疗有效量的式XXVII化合物或包含式XXVII化合物和一种或多种可接受的药物载体的药物组合物。